Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors considerably alter the lipid profile. We sought to examine the rates of ischaemic stroke and neurocognitive deficits in patients treated with and without PCSK9 inhibitors. METHODS AND RESULTS: Randomized controlled trials (RCTs)...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur Heart J Qual Care Clin Outcomes
Asıl Yazarlar: Bajaj, Navkaranbir S, Patel, Nirav, Kalra, Rajat, Ahmad, Amier, Venkatraman, Anand, Arora, Garima, Arora, Pankaj
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2018
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5884103/
https://ncbi.nlm.nih.gov/pubmed/29121222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ehjqcco/qcx037
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller